Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07028268
PHASE2

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors

Official title: A Multicenter, Randomized, Double-Blind, Positively Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2025-06-24

Completion Date

2027-05

Last Updated

2025-12-31

Healthy Volunteers

No

Interventions

DRUG

SHR-2017、Denosumab placebo

SHR-2017; high dose ;Denosumab placebo

DRUG

SHR-2017、Denosumab placebo

SHR-2017; low dose ;Denosumab placebo

DRUG

Denosumab;SHR-2017 placebo

Denosumab;SHR-2017 placebo

Locations (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China